Nov. 18 at 9:42 PM
$SLS FACTS: BAT for Control ARM patients Failed 3 Large Phase 3 Trials conducted by
$ABBV $RHHBY $BMY
- GPs Achieved Statistically Significant 21 Month MOS - in an older (74), All MRD+ (Sicker) Phase 2 Trial Setting. Gps Phase Patients will also recieve 15 treatments in year 1 and 6 in year 2 and 4 in year 3 and beyond vs only 6-12 in year 1 in the P2.
GPS Elicited a 64% Immune Response rate in the P2, its 80% in the P3 per the IDMC unblinded Interim Data.
Ir is Directly Correlated with increased Survival.
-- GPS P 3 Patients will have a Longer MOS than the 21 month P2.
- IDMC unblinded P3 Interim ALL Pooled n.y.m >13.5.
- 128 P3 Enrollment Completed 20 months ago
105 of the 128 Enrolled Nov 2023 are in Trial AT Least 24 months.
- There are several Published AML CR2 Trial Results for BAT, w NIL Surviving Past 20 months - only the rarest of rare Control Arm patients on BAT Remain Alive past 20 months.
There +/- 60 Patient EVENTS Just from the Control ARM and we have yet to See 80.
...
